EP3682015A1 - Means and methods to modulate flavor production in yeast fermentations - Google Patents
Means and methods to modulate flavor production in yeast fermentationsInfo
- Publication number
- EP3682015A1 EP3682015A1 EP18769330.4A EP18769330A EP3682015A1 EP 3682015 A1 EP3682015 A1 EP 3682015A1 EP 18769330 A EP18769330 A EP 18769330A EP 3682015 A1 EP3682015 A1 EP 3682015A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- yeast
- flavor
- protein
- production
- fas2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000796 flavoring agent Substances 0.000 title claims abstract description 155
- 235000019634 flavors Nutrition 0.000 title claims abstract description 146
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 143
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 127
- 238000000034 method Methods 0.000 title claims description 57
- 238000000855 fermentation Methods 0.000 title abstract description 57
- 230000004151 fermentation Effects 0.000 title abstract description 56
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 136
- 241000220317 Rosa Species 0.000 claims abstract description 73
- MDHYEMXUFSJLGV-UHFFFAOYSA-N phenethyl acetate Chemical compound CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 claims description 108
- 101000802894 Dendroaspis angusticeps Fasciculin-2 Proteins 0.000 claims description 98
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims description 94
- 230000035772 mutation Effects 0.000 claims description 79
- 150000007523 nucleic acids Chemical class 0.000 claims description 67
- 108020004707 nucleic acids Proteins 0.000 claims description 58
- 102000039446 nucleic acids Human genes 0.000 claims description 58
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 claims description 52
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 48
- 244000005700 microbiome Species 0.000 claims description 42
- 108010058643 Fungal Proteins Proteins 0.000 claims description 35
- 108010021466 Mutant Proteins Proteins 0.000 claims description 8
- 102000008300 Mutant Proteins Human genes 0.000 claims description 8
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 8
- 230000008488 polyadenylation Effects 0.000 claims description 5
- 230000005030 transcription termination Effects 0.000 claims description 5
- 108700028369 Alleles Proteins 0.000 abstract description 92
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 48
- 230000001965 increasing effect Effects 0.000 abstract description 21
- 239000007788 liquid Substances 0.000 abstract description 3
- 235000021107 fermented food Nutrition 0.000 abstract description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 135
- 235000018102 proteins Nutrition 0.000 description 53
- 102000004169 proteins and genes Human genes 0.000 description 53
- 239000000243 solution Substances 0.000 description 42
- 108020005004 Guide RNA Proteins 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 18
- 210000000349 chromosome Anatomy 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 18
- 108091033409 CRISPR Proteins 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 12
- 238000012217 deletion Methods 0.000 description 11
- 230000037430 deletion Effects 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- 101710163270 Nuclease Proteins 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 238000013507 mapping Methods 0.000 description 9
- 235000013334 alcoholic beverage Nutrition 0.000 description 8
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- 238000012300 Sequence Analysis Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 230000004777 loss-of-function mutation Effects 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 7
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 241000235070 Saccharomyces Species 0.000 description 6
- 150000001242 acetic acid derivatives Chemical class 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 235000013405 beer Nutrition 0.000 description 6
- YYZUSRORWSJGET-UHFFFAOYSA-N ethyl octanoate Chemical compound CCCCCCCC(=O)OCC YYZUSRORWSJGET-UHFFFAOYSA-N 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 229940117955 isoamyl acetate Drugs 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000007844 allele-specific PCR Methods 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 235000019985 fermented beverage Nutrition 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000014101 wine Nutrition 0.000 description 5
- 241000722885 Brettanomyces Species 0.000 description 4
- 241000235649 Kluyveromyces Species 0.000 description 4
- 108020004485 Nonsense Codon Proteins 0.000 description 4
- 241000235088 Saccharomyces sp. Species 0.000 description 4
- 238000010459 TALEN Methods 0.000 description 4
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 4
- 241000235017 Zygosaccharomyces Species 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- QUMXDOLUJCHOAY-UHFFFAOYSA-N alpha-methylbenzyl acetate Natural products CC(=O)OC(C)C1=CC=CC=C1 QUMXDOLUJCHOAY-UHFFFAOYSA-N 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000010573 double replacement reaction Methods 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 230000037433 frameshift Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000012762 unpaired Student’s t-test Methods 0.000 description 4
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000003988 headspace gas chromatography Methods 0.000 description 3
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 3
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 3
- 150000004667 medium chain fatty acids Chemical class 0.000 description 3
- 230000037434 nonsense mutation Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 235000019645 odor Nutrition 0.000 description 3
- 108010001814 phosphopantetheinyl transferase Proteins 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 241000701489 Cauliflower mosaic virus Species 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 102100033295 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 108010016306 Glycylpeptide N-tetradecanoyltransferase Proteins 0.000 description 2
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 2
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101710118447 Plasma membrane ATPase Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 101100236714 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) EEB1 gene Proteins 0.000 description 2
- 101100236715 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) EHT1 gene Proteins 0.000 description 2
- 101100236975 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GAL11 gene Proteins 0.000 description 2
- 101100477706 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SLN1 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- -1 acetate ester Chemical class 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 235000019568 aromas Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 101150078221 fas2 gene Proteins 0.000 description 2
- 230000004136 fatty acid synthesis Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000009655 industrial fermentation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 235000019992 sake Nutrition 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000010572 single replacement reaction Methods 0.000 description 2
- 230000028070 sporulation Effects 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 101150072531 10 gene Proteins 0.000 description 1
- GVEZIHKRYBHEFX-MNOVXSKESA-N 13C-Cerulenin Natural products CC=CCC=CCCC(=O)[C@H]1O[C@@H]1C(N)=O GVEZIHKRYBHEFX-MNOVXSKESA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 101710161460 3-oxoacyl-[acyl-carrier-protein] synthase Proteins 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- 108700037654 Acyl carrier protein (ACP) Proteins 0.000 description 1
- 102000048456 Acyl carrier protein (ACP) Human genes 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 101100512903 Arabidopsis thaliana MES6 gene Proteins 0.000 description 1
- 101000648181 Arabidopsis thaliana Sugar transport protein 1 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000010446 CRISPR interference Methods 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101150089023 FASLG gene Proteins 0.000 description 1
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000987118 Homo sapiens Ran guanine nucleotide release factor Proteins 0.000 description 1
- 101000662686 Homo sapiens Torsin-1A Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 240000003978 Ipomoea coccinea Species 0.000 description 1
- 101000744433 Kluyveromyces lactis (strain ATCC 8585 / CBS 2359 / DSM 70799 / NBRC 1267 / NRRL Y-1140 / WM37) Low-affinity glucose transporter Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102000017343 Phosphatidylinositol kinases Human genes 0.000 description 1
- 108050005377 Phosphatidylinositol kinases Proteins 0.000 description 1
- 102000009569 Phosphoglucomutase Human genes 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102100027976 Ran guanine nucleotide release factor Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101100340191 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) BNA2 gene Proteins 0.000 description 1
- 101100069420 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GRE3 gene Proteins 0.000 description 1
- 101000888248 Schizosaccharomyces pombe (strain 972 / ATCC 24843) High-affinity glucose transporter ght1 Proteins 0.000 description 1
- 101000995910 Solanum lycopersicum Protein NP24 Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 102100037454 Torsin-1A Human genes 0.000 description 1
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 1
- 102100037116 Transcription elongation factor 1 homolog Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010089879 Type I Fatty Acid Synthase Proteins 0.000 description 1
- 101710175177 Very-long-chain 3-oxoacyl-CoA reductase Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- NRAUADCLPJTGSF-ZPGVOIKOSA-N [(2r,3s,4r,5r,6r)-6-[[(3as,7r,7as)-7-hydroxy-4-oxo-1,3a,5,6,7,7a-hexahydroimidazo[4,5-c]pyridin-2-yl]amino]-5-[[(3s)-3,6-diaminohexanoyl]amino]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl] carbamate Chemical compound NCCC[C@H](N)CC(=O)N[C@@H]1[C@@H](O)[C@H](OC(N)=O)[C@@H](CO)O[C@H]1\N=C/1N[C@H](C(=O)NC[C@H]2O)[C@@H]2N\1 NRAUADCLPJTGSF-ZPGVOIKOSA-N 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- GVEZIHKRYBHEFX-UHFFFAOYSA-N caerulein A Natural products CC=CCC=CCCC(=O)C1OC1C(N)=O GVEZIHKRYBHEFX-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- GVEZIHKRYBHEFX-NQQPLRFYSA-N cerulenin Chemical compound C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O GVEZIHKRYBHEFX-NQQPLRFYSA-N 0.000 description 1
- 229950005984 cerulenin Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000010457 gene scissor Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 210000003783 haploid cell Anatomy 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000020938 mating type determination Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000196 olfactory nerve Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-M phenylacetate Chemical compound [O-]C(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-M 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 108091000115 phosphomannomutase Proteins 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000012068 polygenic analysis Methods 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 101710139639 rRNA methyltransferase Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 102200008957 rs387906911 Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000024053 secondary metabolic process Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000037436 splice-site mutation Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000007222 ypd medium Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
- C12P7/16—Butanols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/02—Preparation of other alcoholic beverages by fermentation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/18—Baker's yeast; Brewer's yeast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/22—Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/54—Acetic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01086—Fatty-acyl-CoA synthase (2.3.1.86)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel
Definitions
- the present invention relates to the field of fermentation, more particularly to ethanol production. Even more particularly the present invention relates to altered aroma production during fermentation processes.
- the present invention provides mutant alleles and chimeric genes useful to develop yeast strains to regulate the production of rose flavor during fermentation.
- the invention also relates to the use of such yeast strains for the production of fermented foods and liquids with increased rose flavor.
- Flavor is one of the main defining characteristics of alcoholic beverages with critical importance for their commercial value (1, 2).
- Yeast plays an important role in generating the final aroma profile of alcoholic beverages.
- pleasant flavors to the human palate include the fruity aromas that are largely derived from secondary metabolism of sugar during yeast alcoholic fermentation.
- Esters comprise the largest and most important group. They often have pleasant aromas, low perception thresholds and relatively high concentrations in alcoholic beverages (1, 3, 4). Small changes in ester concentrations can have significant effects on the taste of alcoholic beverages (3).
- Esters are formed from an alcohol and a carboxylic acid linked with coenzyme A. There are two groups of flavor-active esters in fermented beverages, ethyl esters and acetate esters.
- Ethyl esters are formed from ethanol and the acyl-coA derivative of medium- chain fatty acids (MCFA). Among this group, the most important are ethyl hexanoate (anise seed, applelike aroma) and ethyl octanoate (apple, pineapple aroma).
- Acetate esters are formed from acetyl-CoA and an alcohol that can be ethanol (yielding ethyl acetate) or a higher alcohol derived from amino acid metabolism.
- the most flavor-relevant acetate esters are ethyl acetate (solvent-like aroma), isoamyl acetate (banana-like aroma) and 2-phenylethylacetate (honey, rose-like aroma) (1, 4-7).
- ATFl and ATF2 for acetate esters
- EHT1 and EEB1 for ethyl esters (8-12).
- Double deletion of ATFl and ATF2 largely abolishes the production of isoamyl acetate and strongly reduces the production of many other flavor esters, including 2-PEAc.
- the observation that significant production levels are retained in the atflA atf2A strain indicates involvement of other unknown biosynthetic enzymes (8).
- Double deletion of EEB1 and EHT1 caused a considerable, but also only partial reduction in the levels of all ethyl esters, again indicating the presence of additional biosynthetic enzymes (10).
- 2-PEAc phenylethyl acetate production
- 2-PEAc is an acetate ester made by esterification of acetyl-CoA and 2-phenylethanol (2-PE).
- 2-PE is synthesized by degradation of the aromatic amino acid L-phenylalanine.
- BTC.1D and ER18 two random segregants derived from two non-selected diploid strains as parents and identified offspring with high 2- PEAc production.
- TORI encodes a phosphatidylinositol kinase homologue, that regulates multiple cellular processes, including the induction of autophagy (46), the diauxic shift and directly modulates glucose activation and discrimination pathways (47).
- Tori is well known to be involved in nitrogen-regulated processes, such as nitrogen catabolite repression. (49, 50).
- Tori is also involved in the production of 2-phenylethyl acetate. This is demonstrated by a reduction in 2-PeAc production after exchanging wild-type Tori for a defective mutant Tori allele.
- FAS2 encodes the alpha subunit of fatty acid synthetase, a very large, multifunctional protein of 1887 aa, which contributes acyl-carrier, 3-ketoreductase, 3-ketosynthase and phosphopantetheinyl transferase activities to the fatty acid synthetase complex (53) (Fig. 8).
- the latter is composed of six Fasl and six Fas2 subunits.
- FASs microbial type I fatty acid synthases
- the FAS2BTC.1D allele allows to strongly enhance the production of 2-PEAc, even in a strain that already produces a higher level than generally found in fermentations by Saccharomyces cerevisiae strains. This is accomplished with additional positive effects on other flavor compounds and apparently without significant effects on compounds with a negative contribution to the flavor profile.
- the FAS2BTC.1D allele appears to be highly promising for the creation of cisgenic brewing strains with an attractive and novel flavor profile.
- a mutant Fas2 yeast protein comprising an A1136T mutation and/or a V1624I mutation.
- the application also provides a nucleic acid molecule encoding said mutant Fas2 protein, as well as a chimeric gene comprising a promoter which is active in a eukaryotic cell and said nucleic acid molecule encoding the mutant Fas2 yeast protein from the application and a 3' end region involved in transcription termination and/or polyadenylation.
- a vector is provided comprising the above described nucleic acid molecule or chimeric gene.
- a microorganism comprising a mutant Fas2 yeast protein comprising an A1136T mutation and/or a V1624I mutation or comprising the nucleic acid molecule, the chimeric gene or the vector above described.
- said microorganism is an engineered microorganism, even more particularly said microorganism is a yeast.
- the application provides a fermented solution comprising said yeast.
- the use of the mutant Fas2 protein is provided to increase the flavor of a fermented solution.
- said flavor is rose flavor.
- the use of the mutant Fas2 protein is provided to increase the production of 2-phenylethyl acetate, isobutanol, isoamyl alcohol and/or phenylethanol in a microorganism.
- methods are provided to increase the flavor of a fermented solution, said method comprising expressing the Fas2 mutant protein of the application in a yeast, wherein said yeast is used during the production of said fermented solution.
- said flavor is determined by 2-phenylethyl acetate, isobutanol, isoamyl alcohol and/or phenylethanol.
- the application also provides a C-terminally truncated Tori yeast protein.
- said protein lacks residues 216-2470 of a wild type full length Tori protein as defined by SEQ ID No 5.
- a microorganism comprising the above described truncated Tori proteins is provided.
- said microorganism is an engineered microorganism, in other particular embodiments, said microorganism is a yeast.
- the application also provides a fermented solution comprising said yeast.
- a non-functional Tori yeast protein is provided to modulate the flavor profile of a fermented solution. More particularly, said flavor profile modulation is a decrease in the level of rose flavor. Even more particularly, said decrease in rose flavor level is a decreased level of 2-phenylethyl acetate or phenylethanol.
- a method is provided of producing a fermented solution with a reduced level of 2-phenylethyl acetate, said method comprising expressing a non-functional Tori yeast protein in a yeast, wherein said yeast is used during the production of said fermented solution. More particularly, said non-functional Tori protein lacks residues 216-2470 of a wild type full length Tori protein as defined by SEQ ID No 5.
- a method to increase the level of rose flavor or more particularly 2- phenylacetate in a yeast fermentation, said method comprising determining the presence of one or more loss-of-function mutations in the TORI allele of said yeast and restoring said one or more mutations in said yeast to wild-type or replacing the non-functional TORI allele by a wild-type TORI allele, if one of more loss-of-function mutations is present in said yeast's TORI gene.
- said method is disclosed comprising the additional step of expressing the mutant Fas2 protein lacking residues 216-2470 of a wild type full length Tori protein as defined by SEQ ID No 5 in said yeast.
- FIG. 1 Violin density plots of flavor compound production by the segregants from BTC.1D/ER18.
- Fermentations were carried out in 100 mL YP250GlulO% and flavors were measured by GC-FID at the end of the fermentation.
- the width of the violin plot on the X-axis represents the kernel density showing the distribution of values within a dataset, and is thus representative of the number of segregants producing a specific level of flavor compound.
- the flavor production by the parent strains is represented by ⁇ (BTC.1D) and + (ER18). The lowest value indicated represents either the lowest value measured or the detection limit.
- Blue line represents p-values calculated with 0.5 as reference for the whole genome.
- Green line represents p-values calculated with the actual result of the random pool as reference for the whole genome.
- the indicated difference in 2-PEAc production was significant by the unpaired Student t-test; E. TORI allele swapping in the parent strains BTC.1D and ER18. Fermentations were carried out in 100 mL YP250GlulO%. 2-PEAc was measured at the end of the fermentation. The indicated difference in 2-PEAc production was significant by the unpaired Student t- test.
- FIG. 4 Identification of FAS2 as causative gene in QTL2 located on chromosome XVI.
- D. Block 7 contained the FAS2 gene, which turned out to be causative for Q.TL2;
- 2-PEAc was measured at the end of the fermentation. The indicated difference in 2-PEAc production was significant by the unpaired Student t-test; F. FAS2 allele swapping in the parent strains BTC.1D and ER18. Fermentations were carried out in 100 mL YP250GlulO%. 2-PEAc was measured at the end of the fermentation. The indicated difference in 2-PEAc production was significant by the unpaired Student t- test.
- the torlE216* SNP in parent strain ER18 was changed into the wild type TOR1E216 amino acid from parent strain BTC.1D, the FAS2ER18 allele in parent strain ER18 was replaced by the FAS2BTC.1D allele from parent strain BTC.1D, while in the third ER18-derived strain both changes were introduced.
- 2-PEAc production by the parent strain ER18, the single and double replacement strains, and strain 442, one of the top 2-PEAc producing segregants, is shown. Fermentations were carried out in 100 mL YP250GlulO%. 2-PEAc was measured at the end of the fermentation. The indicated difference in 2-PEAc production was significant by the one-way ANOVA with Dunnet's multiple comparison test.
- the torlE216* SNP in parent strain ER18 was changed into the wild type TOR1E216 amino acid from parent strain BTC.ID, the FAS2ER18 allele in parent strain ER18 was replaced by the FAS2BTC.1D allele from parent strain BTC.ID, while in the third ER18-derived strain both changes were introduced.
- Flavor compounds were measured at the end of the fermentation. For each flavor compound, the one-way ANOVA with Dunnet's multiple comparison test was applied to determine significance of any difference with the control strain ER18 (* p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0.001).
- the T0R1*216E and FAS2BTC.1D alleles were engineered into the ER18 strain to obtain the ER18T0R1*216E FAS2BTC.1D strain. Both strains were used for fermentations in 17°P Brouwland brewing wort with 20 ppm 02 at 20°C. Flavor compounds were measured at the end of the fermentation. For each flavor compound, the unpaired t-test was applied to determine significance of any difference between the two strains (* p ⁇ 0.05; **p ⁇ 0.01; ***p ⁇ 0.001).
- Figure 8 Location of the mutant amino acid residues identified in the Fas2 alpha-subunit of the fatty acid synthase complex.
- the huge Fas2 protein contains domains for acyl carrier protein (ACP), ketoacyl reductase (KR), ketoacyl synthase (KS), phosphopantetheinyl transferase (PPT), and two structural domains (SD1 and SD2) (86).
- ACP acyl carrier protein
- KR ketoacyl reductase
- KS ketoacyl synthase
- PPT phosphopantetheinyl transferase
- SD1 and SD2 two structural domains
- Fas2 yeast protein comprising an A1136T mutation and/or a V1624I mutation is provided.
- said mutant protein comprises an A1136T and/or a V1624I mutation.
- a mutant Fas2 yeast protein or a mutant Fas2 protein from Saccharomyces cerevisiae wherein said mutant protein has at least an A1136T mutation or a V1624I mutation.
- said mutant Fas2 protein has an amino acid sequence with a sequence identity to SEQ ID N° 4 preferably of at least 80%, 81%, 82%, 83%,84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% over a range of at least 1500 amino acids or more particularly over a range of at least 1800 amino acids or more particularly over the full length protein.
- said mutant Fas2 protein is the amino acid sequence depicted as SEQ ID No 4.
- the above described mutant Fas2 yeast proteins or mutant Fas2 proteins from Saccharomyces cerevisiae will be referred to as "one of the mutant Fas2 proteins of the application".
- a nucleic acid molecule is provided encoding a mutant Fas2 protein, wherein said mutant Fas2 protein comprises an A1136T and/or a V1624I mutation. This is equivalent as saying that a mutant FAS2 allele is provided, wherein said mutant allele encodes a mutant Fas2 protein comprising an A1136T and/or a V1624I mutation.
- said nucleic acid molecule encodes one of the mutant Fas2 proteins of the application.
- said nucleic acid molecule has a sequence identity to SEQ ID N° 2 preferably of at least 80%, 81%, 82%, 83%,84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% over a range of at least 5000 bases or more particularly over a range of at least 5500 bases or more particularly over the full length nucleic acid molecule.
- said nucleic acid molecule is depicted in SEQ ID No 2. In the rest of this document, the above described nucleic acid molecules encoding a mutant Fas2 yeast protein will be referred to as "one of the nucleic acid molecules of the application”.
- sequence identity of two related nucleotide or amino acid sequences, expressed as a percentage, refers to the number of positions in the two optimally aligned sequences which have identical residues (xlOO) divided by the number of positions compared.
- a gap i.e., a position in an alignment where a residue is present in one sequence but not in the other is regarded as a position with non-identical residues.
- the alignment of the two sequences is performed by the Needleman and Wunsch algorithm (Needleman and Wunsch (1970) J Mol Biol. 48: 443-453).
- sequence alignment can be conveniently performed using standard software program such as GAP which is part of the Wisconsin Package Version 10.1 (Genetics Computer Group, Madison, Wisconsin, USA) using the default scoring matrix with a gap creation penalty of 50 and a gap extension penalty of 3. Sequences are indicated as "essentially similar" when such sequences have a sequence identity of at least about 75%, particularly at least about 80 %, more particularly at least about 85%, quite particularly about 90%, especially about 95%, more especially about 100%, quite especially are identical.
- a chimeric gene comprising a promoter which is active in a eukaryotic cell, one of the nucleic acid molecules of the application and a 3' end region involved in transcription termination and/or polyadenylation.
- a vector is provided comprising said chimeric gene or one of the nucleic acid molecules of the application.
- nucleic acid includes reference to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, encompasses known analogues having the essential nature of natural nucleotides in that they hybridize to single-stranded nucleic acids in a manner similar to naturally occurring nucleotides (e.g. peptide nucleic acids).
- nucleic acid By “encoding” or “encodes” or “encoded”, with respect to a specified nucleic acid, is meant comprising the information for transcription into an NA molecule and in some embodiments, translation into the specified protein or amino acid sequence.
- a nucleic acid encoding a protein may comprise non-translated sequences (e.g., introns) within translated regions of the nucleic acid, or may lack such intervening non- translated sequences (e.g., as in cDNA).
- the information by which a protein is encoded is specified by the use of codons.
- the amino acid sequence is encoded by the nucleic acid using the "universal" genetic code.
- a “chimeric gene” or “chimeric construct” is a recombinant nucleic acid sequence in which a promoter or regulatory nucleic acid sequence is operably linked to, or associated with, a nucleic acid sequence that codes for a mRNA and encodes an amino acid sequence, such that the regulatory nucleic acid sequence is able to regulate transcription or expression of the associated nucleic acid coding sequence.
- the regulatory nucleic acid sequence of the chimeric gene is not operably linked to the associated nucleic acid sequence as found in nature.
- a “promoter” comprises regulatory elements, which mediate the expression of a nucleic acid molecule.
- the nucleic acid molecule must be linked operably to or comprise a suitable promoter which expresses the gene at the right point in time and with the required spatial expression pattern.
- operably linked refers to a functional linkage between the promoter sequence and the gene of interest, such that the promoter sequence is able to initiate transcription of the gene of interest.
- a promoter that enables the initiation of gene transcription in a eukaryotic cell is referred to as being "active".
- the promoter can be operably linked to a reporter gene after which the expression level and pattern of the reporter gene can be assayed.
- Suitable well-known reporter genes include for example beta- glucuronidase, beta-galactosidase or any fluorescent or luminescent protein.
- the promoter activity is assayed by measuring the enzymatic activity of the beta-glucuronidase or beta-galactosidase.
- promoter strength may also be assayed by quantifying mRNA levels or by comparing mRNA levels of the nucleic acid, with mRNA levels of housekeeping genes such as 18S rRNA, using methods known in the art, such as Northern blotting with densitometric analysis of autoradiograms, quantitative real-time PCR or RT-PCR (Heid et al., 1996 Genome Methods 6: 986-994).
- a 3' end region involved in transcription termination or polyadenylation encompasses a control sequence which is a DNA sequence at the end of a transcriptional unit which signals 3' processing or polyadenylation of a primary transcript and is involved in termination of transcription.
- the control sequence for transcription termination or terminator can be derived from a natural gene or from a variety of genes.
- the terminator to be added may be derived from, for example, the TEF or CYCl genes or alternatively from another yeast gene or less preferably from any other eukaryotic or viral gene.
- the promoter in the chimeric gene of the invention is active in yeast.
- said promoter is selected from the list comprising pTEFl (Translation Elongation Factor 1); pTEF2; pHXTl (Hexose Transporter 1); pHXT2; pHXT3; pHXT4; pTDH3 (Triose-phosphate Dehydrogenase) also known in the art as pGADPH (Glyceraldehyde-3-phosphate dehydrogenase) or pGDP or pGLDl or pHSP35 or pHSP36 or pSSS2; pTDH2 also known in the art as pGLD2; pTDHl also known in the art as pGLD3; pADHl (Alcohol Dehydrogenase) also know in the art as pADCl; pADH2 also known in the art as pAD 2; pADH3; pADH4 also known in the art as pZRG5 or pNRC465; pADH
- yeast as used here, can be any yeast useful for industrial applications. Preferable, said yeast is useful for ethanol production, including, but not limited to Saccharomyces, Zygosaccharomyces, Brettanomyces and Kluyveromyces.
- said yeast is a Saccharomyces sp., even more preferably it is a Saccharomyces cerevisiae sp.
- the term "vector" refers to any linear or circular DNA construct comprising the above described chimeric gene of the invention or one of the nucleic acid molecules of the application.
- the vector can refer to an expression cassette or any recombinant expression system for the purpose of expressing one of the nucleic acid molecules of the application in vitro or in vivo, constitutively or inducibly, in any cell, including, in addition to plant cells, prokaryotic, yeast, fungal, insect or mammalian cells.
- the vector can remain episomal or integrate into the host cell genome.
- the vector can have the ability to self-replicate or not (i.e., drive only transient expression in a cell).
- the term includes recombinant expression cassettes that contain only the minimum elements needed for transcription of the recombinant nucleic acid.
- the vector of the invention is a "recombinant vector" which is by definition a man-made vector.
- a microorganism comprising a mutant Fas2 yeast protein is provided wherein said mutant Fas2 protein comprises an A1136T mutation and/or a V1624I mutation.
- a microorganism is provided comprising any of the mutant Fas2 proteins described in this application.
- a microorganism comprising one of the nucleic acid molecules of the application or comprising the chimeric gene of the application or comprising the vector of the application.
- a microorganism is provided comprising a mutant FAS2 allele, wherein said mutant allele encodes a Fas2 protein comprising an A1136T mutation and/or a V1624I mutation.
- said microorganism is an engineered microorganism.
- said microorganism is a yeast.
- said microorganism is an engineered yeast.
- said yeast is useful for ethanol production, including, but not limited to Saccharomyces, Zygosaccharomyces, Brettanomyces and Kluyveromyces.
- said yeast is a Saccharomyces sp., even more preferably it is a Saccharomyces cerevisiae sp.
- said yeast is not BTC.1D or WLP575.
- Means and methods to engineer microorganisms, particularly yeasts are well known by the person skilled in the art. The most known techniques involve traditional genetic transformation of yeast and recombinant DNA techniques.
- nucleases such as zinc-finger nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), meganucleases but especially the C ISP -Cas system.
- ZFNs zinc-finger nucleases
- TALENs Transcription Activator-Like Effector Nucleases
- meganucleases but especially the C ISP -Cas system.
- Nucleases as used herein are enzymes that cut nucleotide sequences. These nucleotide sequences can be DNA or RNA. If the nuclease cleaves DNA, the nuclease is also called a DNase. If the nuclease cuts RNA, the nuclease is also called an RNase.
- ZFN are artificial restriction enzymes generated by fusing a zinc finger DNA- binding domain to a DNA cleavage domain.
- Zinc finger domains can be engineered to target desired DNA sequences, which enables zinc-finger nucleases to target a unique sequence within a complex genome.
- a TALEN ® is composed of a TALE DNA binding domain for sequence-specific recognition fused to the catalytic domain of an endonuclease that introduces double strand breaks (DSB).
- the DNA binding domain of a TALEN ® is capable of targeting with high precision a large recognition site (for instance 17bp).
- Meganucleases are sequence-specific endonucleases, naturally occurring "DNA scissors", originating from a variety of single-celled organisms such as bacteria, yeast, algae and some plant organelles. Meganucleases have long recognition sites of between 12 and 30 base pairs.
- CRISPR interference is a genetic technique which allows for sequence-specific control of gene expression in prokaryotic and eukaryotic cells. It is based on the bacterial immune system-derived CRISPR (clustered regularly interspaced palindromic repeats) pathway and has been modified to edit basically any genome.
- the cell's genome can be cut at a desired location depending on the sequence of the gRNA, allowing existing genes to be removed and/or new one added and/or more subtly removing, replacing or inserting single nucleotides (e.g. DiCarlo et al 2013 Nucl Acids Res doi:10.1093/nar/gktl35; Sander & Joung 2014 Nat Biotech 32:347- 355).
- gRNA synthetic guide RNA
- fermented beverages e.g. beer
- 2-phenylethyl acetate are often positively perceived as having a "honey-like" or "rose-like” flavor. Therefore, the yeast strains which are subject of and are disclosed in the current application are extremely useful in the fermentation industry. Fermented products can have applications in food (for example but not limited to chocolate) and beverages (for example but not limited to beer, wine, sake) as well as in general industry (for example but not limited to bioethanol production) where the production of an enjoyable flavor is desired.
- a fermented solution comprising the yeast strains of this application, or more particularly comprising a yeast strain that comprises a mutant Fas2 yeast protein, wherein said mutant protein comprises an A1136T mutation and/or a V1624I mutation.
- said fermented solution is a fermented beverage or is a fermented solution not suited for consumption.
- a fermented beverage are beer, wine, sake, ...
- a non-limiting example of a fermented solution not suited for consumption is bio-ethanol.
- said fermented beverage is beer.
- mutant Fas2 protein increases the production of 2-phenylethyl acetate but also that of isobutanol, isoamyl alcohol and phenylethanol.
- the observation that the mutant Fas2 protein has a dominant effect is of particular interest for industrial application because the mutation does not have to be homozygous to lead to the mutant phenotype, i.e. increased production of 2-phenylethyl acetate, isobutanol, isoamyl alcohol and phenylethanol.
- mutant Fas2 yeast protein to modulate the flavor profile of a fermented solution
- said mutant Fas2 protein comprises an A1136T mutation and/or a V1624I mutation.
- said mutant Fas2 yeast protein comprises the amino acid sequence depicted as SEQ ID No 4.
- any of the nucleic acid molecules of the application or of any of the chimeric genes comprising one of said nucleic acid molecules or of a vector comprising one of said nucleic acid molecules or one of said chimeric genes to modulate the flavor profile of a fermented solution.
- said flavor profile is a rose flavor profile.
- said modulation is an increase in flavor profile or an increase in flavor, more particularly an increase in rose flavor, even more particularly an increase in the production of 2-phenylethyl acetate and/or phenylethanol.
- 2-Phenylethyl acetate and phenylethanol are two molecules well-known for their rose-like flavor.
- said use is provided to produce a high rose flavor producing yeast or a high 2-phenylethyl acetate producing yeast.
- the application also provides the use of a mutant Fas2 yeast protein to increase the production of 2- phenylethyl acetate, isobutanol, isoamyl alcohol and/or phenylethanol during yeast fermentation, wherein said mutant Fas2 protein comprises an A1136T mutation and/or a V1624I mutation.
- said mutant Fas2 yeast protein comprises the amino acid sequence depicted as SEQ ID No 4.
- the use is provided of any of the nucleic acid molecules of the application or of the chimeric gene comprising said nucleic acid molecule or of the vector comprising said nucleic acid molecule or said chimeric gene to increase the production of 2-phenylethyl acetate, isobutanol, isoamyl alcohol and/or phenylethanol during yeast fermentation.
- a yeast comprising a mutant Fas2 protein comprising an A1136T mutation and/or a V1624I mutation is provided to increase the production of 2-phenylethyl acetate, isobutanol, isoamyl alcohol and/or phenylethanol during fermentation.
- said mutant Fas2 yeast protein comprises the amino acid sequence depicted as SEQ ID No 4.
- the use is provided of any of the mutant Fas2 yeast proteins of the application or any of the nucleic acid molecules of the application or of the chimeric gene comprising said nucleic acid molecule or of the vector comprising said nucleic acid molecule or said chimeric gene to increase the production of at least one molecule from the group consisting of 2-phenylethyl acetate, isobutanol, isoamyl alcohol and phenylethanol in a microorganism.
- any of the mutant Fas2 yeast proteins of the application or any of the nucleic acid molecules of the application or of the chimeric gene comprising said nucleic acid molecule or of the vector comprising said nucleic acid molecule or said chimeric gene is provided to increase the production of 2-phenylethyl acetate, isobutanol, isoamyl alcohol and phenylethanol in a microorganism or during yeast fermentation.
- Increasing the production of rose flavor or “increasing the production of 2-phenylethyl acetate, isobutanol, isoamyl alcohol and/or phenylethanol” as used herein means that the microorganism (in particular embodiments the yeast), that comprises one of the mutant Fas2 yeast proteins of the application produces more rose flavor or more 2-phenylethyl acetate, isobutanol, isoamyl alcohol and/or phenylethanol, compared to a corresponding reference microorganism (in particular embodiments the yeast) lacking said mutant Fas2 protein and comprising a functional or wild-type Fas2 protein.
- Synonyms for increasing are improving, augmenting, boosting, enhancing.
- “increasing the production of rose flavor” or “increasing the production of 2-phenylethyl acetate, isobutanol, isoamyl alcohol and/or phenylethanol” means an at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90, at least 95% or 100% increase or a 2-fold, 3-fold, 5-fold or 10-fold increase in the production of rose flavor or in the production of 2- phenylethyl acetate, isobutanol, isoamyl alcohol and/or phenylethanol.
- "increasing the production of rose flavor” or “increasing the production of 2-phenylethyl acetate, isobutanol, isoamyl alcohol and/or phenylethanol” means obtaining an increased production of said rose flavor or of said 2-phenylethyl acetate, isobutanol, isoamyl alcohol and/or phenylethanol of between 10% and 50%, of between 20% and 60%, of between 30% and 70%, of between 40% and 80% or of between 60% and 150% of the production of said rose flavor or 2-phenylethyl acetate, isobutanol, isoamyl alcohol and/or phenylethanol in conditions where the mutant Fas2 yeast protein of the application is not expressed.
- the skilled person is familiar with methods to analyse and quantify the production of rose flavor or of 2-phenylethyl acetate, isobutanol, isoamyl alcohol or phenylethanol from a sample.
- those molecules were quantified using headspace gas chromatography coupled with flame ionization detection (HS-GC-FID) as clearly described in the materials and method section.
- HS-GC-FID flame ionization detection
- the odor or flavor is the property of a substance that activates the sense of smell. Odor, smell, scent, stench all refer to sensations perceived through the nose by the olfactory nerves. Alcohols with improved flavors or odors are highly desired for blending fermented or alcoholised beverages but also for the industrial production of non-beverage alcohol.
- a method is provided to modulate the flavor profile or more particularly to modulate the rose flavor profile of a fermented solution, said method comprising expressing the Fas2 mutant protein comprising an A1136T and/or a V1624I mutation or expressing the nucleic acid molecule encoding said mutant Fas2 protein or expressing the chimeric gene comprising said nucleic acid molecule in a yeast.
- said yeast is used during the production of said fermented solution.
- said flavor profile is determined by 2-phenylethyl acetate, isobutanol, isoamyl alcohol and/or phenylethanol.
- Fas2 mutant protein With “expressing” or “expression” or “functional expression” of the Fas2 mutant protein, it is meant the transcription and production of said mutant Fas2 protein.
- a method is provided to increase the flavor of a fermented solution or to increase the level of rose flavor in a fermented solution or to increase the production of rose flavor in a fermented solution, said method comprising expressing one of the mutant Fas2 proteins of the application or one of the nucleic acid molecules of the application or the chimeric gene comprising one of said nucleic acid molecules in a yeast.
- said yeast is used during the production of said fermented solution.
- said fermented solution is an alcoholic beverage.
- a method is provided to produce a fermented solution with increased level of rose flavor or to produce a flavor enriched alcohol, said method comprising the step of expressing in a yeast any of the mutant Fas2 proteins any of the nucleic acid sequences or any of the chimeric genes described in the first aspect of current application and in the embodiments of the first aspect.
- said increased level is at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% more or at least 2-fold, at least 3-fold, at least 5-fold or at least 10-fold more or said increased level is between 10% and 50%, of between 20% and 60%, of between 30% and 70%, of between 40% and 80% or of between 60% and 150% more compared to a control yeast not expressing any of the mutant Fas2 proteins or any of the nucleic acid sequences or any of the chimeric genes described in the first aspect of current application and in the embodiments of the first aspect. Said control yeast expressed a wild-type Fas2 protein. Means and methods to determine the expression of protein- encoding genes or to determine the activity of proteins are well-known in the art.
- a method is provided to produce a high rose flavor producing yeast, said method comprising the step of expressing in said eukaryotic cell any of the mutant Fas2 proteins or any of the nucleic acid sequences or any of the chimeric genes described in the first aspect of current application and in the embodiments of the first aspect.
- a "high rose flavor producing yeast” as used in this application refers to a yeast strain that produces a higher amount of 2-phenylethyl acetate and/or phenylethanol compared to a wild-type yeast strain.
- Said wild-type yeast strain is a yeast strain which was not selected and/or engineered to produce a high level of 2-phenylethyl acetate and/or phenylethanol.
- said higher amount is an at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% higher amount or a between 10% and 50%, or a between 20% and 60%, or a between 30% and 70% or a between 40% and 80% bigger amount compared to said wild-type yeast strain.
- said higher amount is a statistical significant higher amount of at least 2-phenylethyl acetate or phenylethanol. "Statistical significant" as used here refers to a p-value of less than 0.5, which is a commonly accepted level for statistical significance and well known by the person skilled in the art.
- the methods further include a step of quantifying at least one rose flavor.
- Said rose flavor can be 2-phenylethyl acetate or phenylethanol.
- said rose flavor is determined by the presence of 2-phenylethyl acetate and/or phenylethanol.
- said microorganisms is a yeast, more particularly a yeast useful for ethanol production, including, but not limited to Saccharomyces, Zygosaccharomyces, Brettanomyces and Kluyveromyces.
- said yeast is a Saccharomyces sp., most particularly it is a Saccharomyces cerevisiae sp. Said yeast strains are particularly useful for industrial fermentation of beverages at conditions wherein increase flavor (more particularly rose flavor) is desired.
- novel mutant allele from the Saccharomyces cerevisiae TORI gene that when expressed homozygously in industrial S. cerevisiae strains or when expressed in the absence of a wild-type (and thus fully functional) TORI gene limits the production of rose flavor, including 2- phenylethyl acetate.
- the novel mutant allele comprises a mutated nucleic acid at position 646 of the open reading frame sequence depicted in SEQ ID No. 6, wherein said mutation introduces a stop codon.
- "Position 646" as used herein refers to the nucleic acid that is 645 positions removed downstream from the first nucleotide (i.e. adenosine) from the start codon. This position is indicated in SEQ ID No. 6 by underlining.
- said mutant TORI allele encodes the C-terminally truncated Tori protein as depicted in SEQ ID No. 7.
- this application provides a C-terminally truncated Tori yeast protein.
- said protein lacks residues 216-2470 of a wild-type full length yeast Tori protein.
- the amino acid sequence of this wild-type full length yeast Tori protein is depicted in or defined by SEQ ID No. 8.
- "Lacking residues 216-2470" is equivalent as saying that the truncated protein lacks residues 216 until 2470 or that the truncated protein is devoid of the amino acid region from 216 until 2470.
- truncated protein refers to a protein which lacks one or more amino acids of the wild-type version of the protein, preferably the protein lacks one or more functional domains present in the wild- type protein. This is typically achieved by a mutation.
- a "C-terminally truncated Tori yeast protein” as used here means that part of the C-terminus of the wild-type yeast Tori protein (defined by SEQ ID No. 8) is missing. This does not mean that the rest of the truncated Tori protein should be identical in length or sequence to the wild-type yeast Tori protein.
- a C-terminally truncated Tori protein lacking residues 216-2470 thus also comprises Tori proteins with additional mutations or truncations besides the C- terminal truncation from residue 216 until residue 2470.
- the C-terminally truncated Tori protein from the application lacks most of the C-terminal part of the wild-type version of the protein. This can be achieved by a mutation specifically inducing premature termination of messenger NA translation.
- said C-terminal truncated protein may be created by a point mutation introducing a stop codon in the reading frame of SEQ ID N° 5, or by a deletion or insertion resulting in a stop codon. In the latter case, the deletion or insertion may cause a frame shift, resulting in a mutant sequence at the C-terminal end of the truncated protein.
- an isolated truncated yeast Tori protein is provided, wherein said protein lacks residues 216-2470 or 215-2470 or 214-2470 or 213-2470 or 212-2470 or 211-2470 or 210-2470 or 200- 2470 or 150-2470 or 100-2470 or 80-2470 or 50-2470 or 20-2470 of a wild-type full length yeast Tori protein defined by SEQ ID No. 8.
- an isolated truncated yeast Tori protein is provided, wherein said protein consists of amino acid 1-215 of a wild type full length Tori protein defined by SEQ ID No 8.
- a C-terminally truncated Tori yeast protein is provided as depicted in SEQ ID No. 7.
- a nucleic acid molecule is provided encoding one of the above described C-terminally truncated Tori yeast proteins. Any of said nucleic acid molecules is thus equivalent to a mutant yeast TORI allele. In a most particular embodiment, said mutant yeast TORI allele is depicted in SEQ ID No. 6.
- a microorganism comprising one of the above described C-terminally truncated Tori yeast proteins or comprising a nucleic acid molecule encoding one of said truncated Tori proteins.
- a microorganism is provided comprising the C-terminally truncated Tori yeast protein as depicted in SEQ ID No. 7 or comprising the mutant Tori allele depicted in SEQ ID No. 6.
- said microorganism is an engineered or recombinant microorganism.
- said microorganism is a yeast.
- said microorganism is an engineered or recombinant yeast.
- said yeast is useful for ethanol production, including, but not limited to Saccharomyces, Zygosaccharomyces, Brettanomyces and Kluyveromyces. Even more particularly, said yeast is a Saccharomyces sp., most particularly it is a Saccharomyces cerevisiae sp. Said yeast strains are particularly useful for industrial fermentation at conditions wherein too much flavor, more particularly too much rose flavor is produced.
- the application also provides a fermented solution comprising one of the above described yeasts.
- said fermented solution is an alcoholic beverage, for example but not limited to beer.
- said fermented solution is a non-food or non-beverage solution, for example but not limited bio-ethanol.
- a non-functional Tori yeast protein or of a mutant TORI allele is provided to modulate the flavor profile of a fermented solution.
- said flavor profile modulation is a decrease in flavor.
- said flavor is rose flavor.
- the use of a non-functional Tori yeast protein or of a mutant TORI allele is provided to reduce the production of 2-phenylethyl acetate or phenylethanol in a fermented solution.
- a non-functional Tori yeast protein is a mutant Tori yeast protein with a disrupted, partially deleted or completely deleted function.
- the one or more mutations that lead to a nonfunctional Tori can be frame shift mutations, nonsense mutations or missense mutations.
- said mutation is a nonsense mutation, thus leading to a premature stop codon.
- the use of a C-terminally truncated Tori protein is provided to modulate the flavor profile of a fermented solution.
- the use of a nonfunctional Tori yeast protein or of a mutant yeast Tori allele encoding said non-functional Tori protein is provided to modulate the flavor profile of a fermented solution, wherein said mutant Tori protein is depicted in SEQ ID No. 7 and said mutant allele is depicted in SEQ ID No. 6.
- said modulation of flavor profile is a reduction in flavor, more particularly rose flavor, even more particularly a reduction of 2-phenylethyl acetate and/or phenylethanol.
- the use of a mutant yeast TORI allele is provided to limit the production of rose flavor in a microorganism or to produce a fermented solution with a reduced level of rose flavor or to produce a flavor neutral alcohol.
- the use of a yeast is provided to limit the production of rose flavor during yeast fermentation or to produce a fermented solution with a reduced level of rose flavor or to produce a flavor neutral alcohol, wherein said yeast comprises a disrupted, partially deleted or completely deleted TORI allele.
- a yeast is provided to limit the production of rose flavor during yeast fermentation or to produce a fermented solution with a reduced level of rose flavor or to produce a flavor neutral alcohol, wherein said yeast comprises the mutant yeast TORI allele depicted in SEQ ID No. 6.
- the use of a mutant yeast TORI allele, wherein said allele encodes a nonfunctional Tori protein or the use of a yeast comprising said mutant yeast TORI allele is provided, to produce a low rose flavor producing yeast.
- said rose flavor is selected from the list consisting of 2-phenylethyl acetate and phenylethanol.
- a yeast in another aspect, is provided to decrease rose flavor production in a fermented solution or to produce a fermented solution with a reduced level of rose flavor or to produce a rose flavor neutral alcohol, wherein said yeast has a disrupted, partially deleted or completely deleted functional expression of TORI.
- said rose flavor is 2-phenylethyl acetate or phenylethanol.
- a method to limit the production of rose flavor during yeast fermentation or to produce a fermented solution with a reduced level of rose flavor or to produce a flavor neutral alcohol comprising the step of disrupting, partially deleting or completely deleting Tori function in a yeast, wherein said yeast is used during the production of said fermented solution or said flavour neutral alcohol.
- a method to limit the production of rose flavor during yeast fermentation or to produce a fermented solution with a reduced level of rose flavor or to produce a flavor neutral alcohol is provided, said method comprising the step of replacing a wild-type TORI allele with the mutant yeast TORI allele depicted in SEQ ID No. 6 in yeast.
- a method is provided to decrease, to limit or reduce the 2-phenylethyl acetate production in a yeast-mediated fermentation, said method comprising disrupting, partially deleting or completely deleting Tori function in said yeast.
- Disrupted, partially deleted or completely deleted function or “disrupting, partially deleting or completely deleting the functional expression” is equivalent as saying partially or completely inhibiting the formation of a functional mRNA molecule encoding Tori.
- Means and methods to disrupt, partially deleted or completely delete a gene or protein are well known in the art. The skilled person can select from a plethora of techniques to affect the expression or function of Tori. One very efficient technique is the Crispr/Cas technology which has also been used in this application e.g. in Examples 3 and 4.
- disruption, partial deletion or complete deletion can for example be achieved by removing or disrupting a gene encoding Tori or by mutations in the promoter of a gene encoding Tori.
- Non-limiting examples are knock-outs or loss-of-function mutations but also gain-of-function mutations and dominant negative mutations can disrupt the functional expression or inhibit the formation of a functional mRNA molecule.
- a "knock-out" can be a gene knockdown (leading to reduced gene expression) or the gene can be knocked out by a mutation such as, a point mutation, an insertion, a deletion, a frameshift, or a missense mutation by techniques known in the art.
- the lack of transcription can e.g. be caused by epigenetic changes (e.g. DNA methylation) or by loss-of-function mutations.
- a "loss-of-function” or "LOF” mutation as used herein is a mutation that prevents, reduces or abolishes the function of a gene product as opposed to a gain-of-function mutation that confers enhanced or new activity on a protein.
- the disclosed TORI mutant allele has a loss-of-function effect and is recessive, meaning that the mutation has to be homozygous to lead to the mutant phenotype.
- Both dominant negative or LOF mutations can be caused by a wide range of mutation types, including, but not limited to, a deletion of the entire gene or part of the gene, splice site mutations, frame-shift mutations caused by small insertions and deletions, nonsense mutations, missense mutations replacing an essential amino acid and mutations preventing correct cellular localization of the product.
- “Limiting the production of rose flavor” or “limiting rose flavor production” as used herein means that the microorganism (in particular embodiments the yeast), that comprises a disrupted, partially deleted or completely deleted Tori produces less rose flavor, more particularly less of at least 2-phenylethyl acetate or phenylethanol, compared to a corresponding reference microorganism (in particular embodiments the yeast) lacking a disrupted, partially deleted or completely deleted Tori.
- Synonyms for limiting are reducing, lowering, restricting, constraining, decreasing, lessening, diminishing.
- limiting the production of rose flavor or "a reduced level of rose flavor” means an at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90, at least 95% or 100% reduction in the production of said rose flavor or more particularly of 2-phenylethyl acetate or phenylethanol.
- “limiting the production of rose flavor” or “a reduced level of rose flavor” means obtaining a reduced production of rose flavor of between 10% and 50%, of between 20% and 60%, of between 30% and 70% or of between 40% and 80% of the production of rose flavor in conditions where Tori is not disrupted, not partially deleted or not completely deleted.
- a method to increase the level of rose flavor in a yeast fermentation, said method comprising:
- said rose flavor is 2-phenylethyl acetate.
- said loss-of- function mutation is a reduce-of-function mutation.
- said method comprises the additional step of expressing a mutant Fas2 protein in said yeast, wherein said mutant Fas2 protein comprises an A1136T mutation and/or a V1624I mutation.
- Example 1 Flavor profile of a set of segregants obtained from unselected parent strains
- the SNP variant frequency was used for QTL mapping using the Next Generation Sequencing Eclipse Plugin (NGSEP) program in order to identify the genomic loci linked to high 2-PEAc production.
- NGSEP Next Generation Sequencing Eclipse Plugin
- the sequence reads from the parental strains and the pool were first aligned to the reference S288c genome sequence and SNPs between the two parent strains with a coverage of at least 20 times were selected following previous polygenic analysis protocols (17, 38). SNPs with the reference genome sequence but absent between the parent strains were filtered out using the NGSEP program.
- the SNP variant frequency was plotted against the chromosomal position using the RStudio 0.99.903 program, generating the QTL map (Fig. 2).
- This haploid strain showed a 2-PEAc production of about 4 ppm and contained the superior allele in the region under investigation.
- the non-essential genes MOG1, BNA2 and TORI were deleted in this superior segregant by replacing them with a nourseothricin resistance marker cassette.
- the deletion strains were evaluated by fermentation for flavor production and a significant decrease in 2-PEAc production was observed only for the 442 torlA strain (Fig. 3D).
- Figure 3D shows that the 442 torlA and 442 torlE216* strains produced a similarly reduced level of 2-PEAc, which was approximately 30% lower than that of the wild type strain. This indicated that TORI affected 2-PEAc production and that the torlE216* allele, derived from ER18, behaved as a loss of function allele.
- the TORI alleles were also exchanged in the parent strains.
- the stop codon mutation E216* was introduced in the BTC.1D parent, while the E216 residue was restored in the ER18 parent, both via CRISPR/Cas9 methodology.
- the 2-PEAc production by the BTC.1D torlE216* and ER18 TOR1E216 strains was evaluated in small-scale fermentations.
- the introduction of the early stop codon into the BTC.1D parent resulted in a decrease with about 40% in 2-PEAc production, while ER18 showed a 35% increase when the E216 residue was restored and the complete wild type Tor protein was therefore expressed (Fig. 3E).
- Direct replacement of the blocks of genes was required since the superior segregant 442 is haploid and some genes in the blocks are essential. Direct replacement was achieved using CRISPR/Cas9 methodology using two gRNAs, one targeting a sequence upstream of the first SNP of interest and the other a sequence downstream of the last SNP of interest.
- the donor DNA was PCR-amplified from the ER18 parent, which apparently contained the genomic DNA with the inferior causative allele.
- the bulk replacement strains for each block of genes were used in small-scale fermentations and 2-PEAc production was measured at the end of the fermentation. This revealed a conspicuous drop in 2-PEAc production specifically with the 442 strain in which block number 7 with the BTC.ID parent sequence had been exchanged for the sequence of the ER18 parent strain (Fig. 4E).
- the length of block 7 was 6.4kb and it contained one gene (FAS2) with about 500bp of its promotor and terminator. Since FAS2 encodes the alpha subunit of fatty acid synthetase, it appeared to be the best candidate causative gene in this block (Fig. 4D).
- Comparison of the FAS2 gene sequence of the BTC.ID and ER18 parent strains revealed 5 non-synonymous mutations in the open reading frame. We checked the occurrence of those amino acid mutations in 39 strains for which the whole genome sequence is available at the Saccharomyces Genome Database. The result is shown in Table 1. Fas2 is a highly conserved protein and among the five amino acid changes found in the BTC.ID parent sequence, two were not found in any sequenced strain.
- BTC.ID contained threonine, while all the other strains contained alanine while at position 1624 in the amino acid sequence, BTC.ID contained isoleucine, while it was in all other strains a valine.
- BTC.ID superior allele FAS2A57T, S565N, A1136T, V1624I, S1800N
- FAS2BTC.1D the inferior allele from ER18 will be fas2ER18.
- Example 5 Establishing the superior phenotype by replacing the TORI and FAS2 alleles in the ER18 parent strain
- Strain 16D is a haploid segregant of JT22689, a strain used in "sturm” must fermentations (Austria) (21).
- ER18 (MATa) and 16D (MATa) contain the same wild type TORI allele (T0R1*216E or TOR1E216, respectively). Therefore, any difference between diploid strains having either ER18 T0R1*216E or ER18 T0R1*216E FAS2BTC.1D is only due to the effect of the FAS2BTC.1D allele.
- Example 6 Production of the other flavor compounds in the ER18 strains engineered for high 2-PEAc production
- the increase in phenylethanol which also has a rose flavor, may strengthen the effect of the enhanced 2-PEAc level on total rose flavor impression.
- the higher increase in phenylethanol compared to isobutanol and isoamyl alcohol may explain why there was only a significant increase in phenylethyl acetate and not in isobutyl acetate and isoamyl acetate.
- the FAS2 allele caused a strong reduction in the production of ethyl hexanoate and ethyl octanoate, which may be due to reduced activity of Fas2 for synthesis of medium-chain fatty acids and/or indicate competition between the synthesis of these compounds and the synthesis of 2-PEAc. For acetaldehyde, there was no significant difference among the four strains.
- the double replacement strain containing TOR1E216 and FAS2BTC.1D, was also compared with the parent strain in wort fermentations (Fig. 7). This revealed a 60% increase in the level of 2-PEAc, confirming the potency of the superior alleles to enhance rose flavor production. As in YP medium, the level of isobutanol and isoamylalcohol, but not that of phenyl ethanol, was significantly increased. The double replacement strain also showed a significant increase in both isoamyl alcohol and isoamyl acetate, leaving the ratio unchanged, as opposed to YP medium where only isoamyl alcohol increased and not isoamyl acetate. Interestingly, in wort medium there was no significant drop in the production of ethyl hexanoate and ethyl octanoate, as opposed to YP medium.
- ER18 Segregant of Ethanol Red Industrial yeast strain used MCB, KU Leuven
- Yeasts were grown in YPD medium [2% (w/v) glucose, 2% (w/v) peptone, 1% (w/v) yeast extract] shaking at 200 rpm and at 30 °C.
- YPD medium 2% (w/v) glucose, 2% (w/v) peptone, 1% (w/v) yeast extract
- 1.5% (w/v) Bacto agar was added.
- the S. cerevisiae yeast strains used in this study are listed in Table 2.
- Escherichia coli cells DH5, Invitrogen
- LB Luria Broth
- yeast extract containing 0.5% (w/v) yeast extract, 1% (w/v) Bacto tryptone, and 1% (w/v) sodium chloride (pH 7.5).
- LB Luria Broth
- Bacto tryptone 1%
- sodium chloride sodium chloride
- Flavor compound screening was performed in YP250GlulO% (0.27% yeast extract (Merck), 0.54% bacto peptone (Oxoid) to a total predicted nitrogen content of 250 mg/L, which is in the same range as beer and wine fermentations, and 10% (w/v) glucose.
- the predicted nitrogen content was based on information of titratable nitrogen from the suppliers.
- unhopped wort was used [17 "Plato, 18.8% (w/v) malt extract, 2.068 ppm ZnSO 4 .7H 2 0].
- Yeast cells were first cultivated overnight in 3 mL of YPD2% in a shaking incubator at 30 °C, 200 rpm. This pre-culture was used to inoculate 100 mL of YP250GlulO% (w/v) with an initial OD600 nm of 0.1. Fermentation was carried out at 25°C in 100 ml fermentation tubes, previously validated against European Brewing convention (EBC) tall tubes, fitted with a water lock in order to create semi-anaerobic conditions, mimicking large scale fermentations. Agitation was performed with a magnetic rod at 130 rpm. Fermentation progress was monitored by weight loss due to CO2 release. Samples were taken at the end of the fermentations for headspace GC-FID analysis. Wort fermentations were performed at 20°C and yeast was inoculated to an initial OD600 nm of 2.0.
- EBC European Brewing convention
- GC-FID flame ionization detection
- Injection block and flame ionization detector temperatures were kept constant at 220 and 250 °C, respectively.
- Oven temperature was kept at 40 °C for 2 min, then increased to 240 °C at a rate of 15 °C/min.
- Helium was used as carrier gas at a flow rate of 2.0 ml/s.
- GC operating conditions were used as follows: injection volume lmL; split rate 1:25; split flow 50mL/min.
- Standard procedures were used for sporulation and tetrad dissection (79) and for mating type determination by PCR with primers for the MAT locus and MATa and MATa DNA (80).
- Yeast cells were transformed by electroporation (81). Standard molecular biology protocols were used in this work.
- Segregants were grown separately in 3ml YPD and pooled together by OD600 nm with the purpose of getting approximately equal amounts of DNA for each strain.
- Genomic DNA was extracted and purified with the "Masterpure Yeast DNA purification kit" from Epicentre in order to obtain high quality genomic DNA. At least 10 ⁇ g of DNA per pool was provided to Beijing Genomics Institute (BGI, Hong Kong, China) for whole genome sequence analysis, which was performed with the lllumina platform (HiSeq2000). Assembly and mapping were done with NGSEP (Next Generation Sequencing Eclipse Plugin) (82). Significance tests used to determine quantitative trait loci were carried out as described by Claesen et al. (83).
- the CRISPR-Cas9 technology was applied by using the pTEF-Cas9-KanMX plasmid (CrispR-mediated gene inactivation or replacement, single copy, Cas9 behind TEF-promotor, KanMX marker) which was derived from the p414-TEFlp-Cas9-CYClt plasmid (27).
- the pTEF-Cas9-KanMX plasmid was created by introducing the KanMX4 marker into Kpnl-digested p414-TEFlp-Cas9-CYClt.
- gRNAs were designed, for lx, 2x or 3xgRNA approach.
- Specific gRNAs were assembled by using the Gibson Assembly Kit into the Xhol-EcoRV-digested P58 vector.
- P58 was derived from p426-SNR52p-gRNA.CANl.Y-SUP4t (27). It was created by assembling the HPH marker and the universal CRISPR gRNA cloning site into the p426-SNR52p-gRNA.CANl.Y-SUP4t backbone.
- flanking regions 1 and 2 A specific gRNA without PAM-site and flanked by the flanking regions 1 and 2 was designed.
- Flanking region 1 (promotor): GCAGTGAAAGATAAATGATC (SEQ ID No 9)
- Flanking region 2 (terminator): GTTTTAGAGCTAGAAATAG (SEQ ID No 10)
- oligomers were hybridized and assembled into the Xhol-EcoRV-digested P58 vector with the Gibson Assembly Kit.
- oligomers were dissolved in STE-buffer (10 mM Tris pH 8.0, 50 mM NaCI, 1 mM EDTA) at a concentration of 500 ⁇ .
- Equimolar concentrations of the forward and reverse primers were combined and heated at 94°C (4 °C/min) for 3 min and slowly cooled down (to 75 °C at 0.05 °C/min, and then cooled to 10°C at 0.02 °C/min).
- the pJET-2xgRNA plasmid was derived from pJETl,2-blunt (ThermoScientific) and contains a module consisting of the gRNA terminator and promotor. The amplification of this module, flanked by gRNA sequences, allows the addition of more gRNAs in the regular gRNA plasmids.
- a specific gRNA without PAM-site and flanked by the flanking regions 1 and 2 was designed, one before the first SNP of interest and the other after the last SNP of interest.
- Forward gRNAl and reverse gRNA2 oligomers were used to amplify the module from pJET-2xgRNA. The amplification of this module flanked with gRNA sequences, allows the addition of more gRNAs in the regular gRNA plasmids.
- the amplification product (505bp) was assembled into the Xhol-EcoRV-digested P58 vector using the Gibson Assembly Kit. Design guide RNA targets
- Proper gRNA targets were selected based on the presence of natural SNPs between inferior and superior allele at the protospacer adjacent motif (PAM) sequence or the 8 bp of DNA preceding the PAM sequence, described as the most important for specificity (84, 85).
- PAM protospacer adjacent motif
- Donor DNA was a 71bp-oligomer containing the desired mutation and 35bp identical sequences on each side: TAAAGTCTTGCCTAGAATGGCTTACTGCCTCCACGTAAAAGAATTCATTCTCAAGTTCGAAGCCAGACCAT (SEQ ID No ll)
- the forward and reverse sequences were ordered and then hybridized.
- Donor DNA was PCR-amplified from the BTC.1D parent, which contains the superior allele on chromosome XVI. Donor DNA contained 500-800 bp of flanking sequence similarity.
- Point mutations were introduced with the CRISPR/Cas9 technology, using a single gRNA. Bulk replacements on chromosome XVI were performed by using the 2x gRNA approach. In haploid cells the lx or 2xgRNA approach was used. Cells were first transformed with 250 ng of pTEF-Cas9-KanMX plasmid by electroporation. Cas9-transformants were pre-grown in 3mL YPD-geneticin (200 ⁇ g/ml), 30 °C, overnight. This culture was used to inoculate 50ml YPD-geneticin to an initial OD 0.2.
- Cells were transformed by electroporation using 500 ng of the gRNA plasmid and 1000 ng of donor DNA (or 2 ⁇ of 250 ⁇ duplexed oligomers, for the point mutation). Transformants were selected on solid YPD2% + 200 ⁇ g/ml geneticin + 300 ⁇ g/ml hygromycin B. Sequences
- SEQ ID No 1 wild-type FAS2 allele (present in inferior ER18)
- SEQ ID No 2 mutant FAS 2 allele (present in superior BTC.1D)
- SEQ ID No 3 wild-type FAS2 protein sequence (present in inferior ER18)
- SEQ ID No 4 mutant FAS2 protein sequence (present in superior BTC.1D)
- SEQ ID No 5 wild-type TORI allele (present in superior BTC.1D)
- SEQ ID No 6 mutant TORI allele (present in inferior ER18)
- SEQ ID No 7 mutant TORI protein sequence (present in inferior ER18)
- SEQ ID No 8 engineered TORI protein sequence References
- Flavor-active esters adding fruitiness to beer. J Biosci Bioeng 96:110-118.
- Saccharomyces cerevisiae EHTl and EEBl genes encode novel enzymes with medium-chain fatty acid ethyl ester synthesis and hydrolysis capacity. J Biol Chem 281:4446-4456.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1714557.4A GB201714557D0 (en) | 2017-09-11 | 2017-09-11 | Means and methods to modulate flavor production in yeast fermentations |
PCT/EP2018/074432 WO2019048699A1 (en) | 2017-09-11 | 2018-09-11 | Means and methods to modulate flavor production in yeast fermentations |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3682015A1 true EP3682015A1 (en) | 2020-07-22 |
Family
ID=60117253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18769330.4A Withdrawn EP3682015A1 (en) | 2017-09-11 | 2018-09-11 | Means and methods to modulate flavor production in yeast fermentations |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3682015A1 (en) |
BR (1) | BR112020004048A2 (en) |
GB (1) | GB201714557D0 (en) |
WO (1) | WO2019048699A1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6587087B2 (en) * | 2014-06-06 | 2019-10-09 | 新潟県 | FAS2 protein, FAS2 gene and caprylic acid high productivity yeast |
-
2017
- 2017-09-11 GB GBGB1714557.4A patent/GB201714557D0/en not_active Ceased
-
2018
- 2018-09-11 WO PCT/EP2018/074432 patent/WO2019048699A1/en unknown
- 2018-09-11 BR BR112020004048-7A patent/BR112020004048A2/en not_active Application Discontinuation
- 2018-09-11 EP EP18769330.4A patent/EP3682015A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2019048699A1 (en) | 2019-03-14 |
BR112020004048A2 (en) | 2020-09-08 |
GB201714557D0 (en) | 2017-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Trindade de Carvalho et al. | Identification of novel alleles conferring superior production of rose flavor phenylethyl acetate using polygenic analysis in yeast | |
US9862974B2 (en) | Cyanobacterium sp. host cell and vector for production of chemical compounds in cyanobacterial cultures | |
WO2018111194A1 (en) | Targets for improving terpene production in rhodosporidium toruloides | |
UA111813C2 (en) | THE METHOD OF PREPARING A QUALITY WITH THE APPLICATION OF Yeast | |
JP6562950B2 (en) | Dreamenol synthase and method for producing dreammenol | |
EP3294897A1 (en) | A method for producing resveratrol | |
Takahashi et al. | Isolation and characterization of sake yeast mutants with enhanced isoamyl acetate productivity | |
CN110760453B (en) | Genetically engineered yeast strain for high-yield phenylethyl acetate, construction method thereof and method for producing phenylethyl acetate | |
CN106460014B (en) | Drimenol synthase and method for producing drimenol | |
US20200056210A1 (en) | Sesquiterpene synthases for production of drimenol and mixtures thereof | |
EP3682015A1 (en) | Means and methods to modulate flavor production in yeast fermentations | |
JP6748108B2 (en) | Production of aromatic compounds | |
Liang et al. | MptriA, an acetyltransferase gene involved in pigment biosynthesis in M. purpureus YY-1 | |
US20190093131A1 (en) | Drimenol synthases iii | |
CA3240648A1 (en) | Methods of preventing inhibition of flavour production in yeast | |
US11186807B2 (en) | Reducing acetate ester production in yeast | |
KR102090790B1 (en) | Novel alcohol acetyltransferases from Saccharomycopsis fiburigera and method for producing acetate esterases using the same | |
WO2021105212A1 (en) | Means and methods to modulate acetic acid tolerance in industrial fermentations | |
Muñoz-Miranda et al. | CRISPRi-induced transcriptional regulation of IAH1 gene and its influence on volatile compounds profile in Kluyveromyces marxianus DU3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200318 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D Owner name: VIB VZW |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20220401 |